1. Introduction

Self-dissolving drug delivery implants are advanced biomedical products designed to release therapeutic substances inside the human body and gradually degrade, dissolve, or undergo biological resorption without requiring surgical removal in appropriate circumstances. They may be manufactured using biodegradable polymers, hydrogels, or other biocompatible materials and can deliver medicines over a predetermined period.

Examples include biodegradable implants used for controlled drug delivery, certain long-acting contraceptive systems, drug-eluting biodegradable scaffolds, and implants designed to release therapeutic agents at a particular anatomical site.

The governance of these implants concerns their safety, efficacy, manufacturing quality, clinical testing, informed consent, intellectual property, post-market monitoring, and environmental and ethical implications. Since they combine pharmaceutical substances with implantable materials, their regulation may involve both drug and medical-device requirements.

2. Meaning and Objectives of Governance

Governance refers to the legal, institutional, ethical, and technical framework governing the development, approval, manufacture, distribution, implantation, monitoring, and disposal of self-dissolving drug delivery implants.

Its principal objectives are:

To ensure that the implant releases the intended drug dose at the appropriate rate.

To prevent toxicity caused by degradation products or unintended drug release.

To ensure biocompatibility and minimise inflammation, infection, and tissue damage.

To establish accountability for manufacturers, healthcare professionals, researchers, and regulators.

To protect patient autonomy, privacy, and access to effective treatment.

3. Legal and Regulatory Framework in India

A. Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act, 1940, establishes the principal statutory framework for regulating drugs in India. Depending on the product's composition, intended purpose, and regulatory classification, the Act and applicable rules govern drug quality, manufacture, import, distribution, and sale.

Section 3(b) defines drugs, while section 3(b)(iv), read with the relevant notifications, provides the statutory basis for regulating specified medical devices as drugs. A drug-containing implant must therefore be assessed according to its intended primary action and the applicable regulatory classification.

B. Medical Devices Rules, 2017

The Medical Devices Rules, 2017, regulate medical devices under the Drugs and Cosmetics Act. They establish requirements relating to risk classification, manufacturing and import licensing, quality management, clinical investigation, and conformity with applicable standards.

The Central Drugs Standard Control Organisation (CDSCO) is the principal national regulatory authority. The applicable requirements depend on whether the product is regulated as a drug, a medical device, or a combination of regulated constituents. <Entity value="CDSCO" category="organization" disambig="India's national drug and medical-device regulator"/> provides the relevant regulatory framework.

C. New Drugs and Clinical Trials Rules, 2019

Where an implant contains a new drug or otherwise falls within the applicable definition of a new drug, the New Drugs and Clinical Trials Rules, 2019, may govern permission for clinical trials and regulatory approval. Ethical review, informed consent, participant safety, and compensation requirements must be addressed where applicable.

D. Manufacturing and Quality Standards

Manufacturers must establish validated processes to control implant composition, sterility, drug-release kinetics, mechanical properties, degradation rates, packaging, and shelf life. Applicable good manufacturing practice requirements and recognised standards for biological evaluation and risk management should be followed.

4. Essential Governance Principles

A. Safety and Biocompatibility

The implant must not cause unacceptable local or systemic toxicity. Testing should examine tissue compatibility, inflammation, infection risk, degradation products, and possible organ damage. Particular attention is required where degradation changes the local pH or releases potentially harmful substances.

B. Controlled Drug Release

The manufacturer must demonstrate that the implant delivers the intended amount of medicine over the specified period. Premature degradation may cause under-treatment, while rapid or unpredictable release may cause overdose.

C. Clinical Trials and Informed Consent

Clinical investigations must be appropriately authorised and ethically reviewed. Patients should receive understandable information concerning the implant's benefits, risks, expected duration, possible complications, alternatives, and whether removal or additional intervention may become necessary.

D. Manufacturing Accountability

Manufacturers must maintain traceability of materials, production batches, sterilisation processes, packaging, and distribution. Significant design or manufacturing changes may require additional validation or regulatory review.

E. Post-Market Surveillance

After approval, adverse events, implant failures, unexpected degradation, ineffective drug delivery, and serious complications must be investigated and reported under applicable requirements. Corrective action, product recalls, and updated warnings may be necessary.

5. Ethical and Human Rights Considerations

Self-dissolving implants may reduce the need for removal surgery, but their internal placement and limited reversibility raise ethical concerns. Patients should not be subjected to implantation without valid consent, except where a legally recognised emergency exception applies.

Healthcare professionals should explain that dissolution does not necessarily mean immediate elimination of the drug or its degradation products. Patients should also be informed about long-term uncertainty, follow-up requirements, and available alternatives.

Equitable access, affordability, protection of clinical data, and avoidance of misleading claims are additional governance priorities.

6. Conclusion

The governance of self-dissolving drug delivery implants requires coordinated regulation of pharmaceutical performance, implant safety, manufacturing quality, clinical research, informed consent, and post-market surveillance. In India, the Drugs and Cosmetics Act, 1940, the Medical Devices Rules, 2017, and, where applicable, the New Drugs and Clinical Trials Rules, 2019, form important elements of this framework. Effective governance must ensure that biodegradability is demonstrated through scientific evidence rather than assumed from the material's composition, while maintaining patient safety, transparency, accountability, and access to appropriate treatment.